Abstract
0.62, 95% CI: 0.45-0.85) but remained inconclusive in randomized trials (OR 0.63, 95% CI: 0.20-2.01). MI rate was similar with both anticoagulants. CONCLUSION: Among patients undergoing transfemoral PCI, the benefit of bivalirudin over UFH monotherapy is driven by a significant reduction in major bleeding with similar rates of MACE. As PCI practice moves toward other bleeding avoidance strategies like radial approach, future studies should focus on the interaction between anticoagulant strategy and access site choice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
